Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$48000.0.

  • Taysha Gene Therapies' Cash from Investing Activities fell 3714.29% to -$48000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$344000.0, marking a year-over-year increase of 1088.08%. This contributed to the annual value of -$363000.0 for FY2024, which is 9506.26% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Cash from Investing Activities of -$48000.0 as of Q3 2025, which was down 3714.29% from $62000.0 recorded in Q2 2025.
  • Taysha Gene Therapies' Cash from Investing Activities' 5-year high stood at $62000.0 during Q2 2025, with a 5-year trough of -$11.4 million in Q1 2022.
  • Over the past 4 years, Taysha Gene Therapies' median Cash from Investing Activities value was -$201000.0 (recorded in 2024), while the average stood at -$2.2 million.
  • Within the past 5 years, the most significant YoY rise in Taysha Gene Therapies' Cash from Investing Activities was 23000.0% (2024), while the steepest drop was 51875.0% (2024).
  • Taysha Gene Therapies' Cash from Investing Activities (Quarter) stood at -$2.4 million in 2022, then soared by 99.58% to -$10000.0 in 2023, then soared by 230.0% to $13000.0 in 2024, then plummeted by 469.23% to -$48000.0 in 2025.
  • Its Cash from Investing Activities stands at -$48000.0 for Q3 2025, versus $62000.0 for Q2 2025 and -$371000.0 for Q1 2025.